In an era of rapid technological advancement
“Our goal is clear: providing tangible results for the clients we support, ultimately making a difference in patients’ lives.”
OLIVIER GRANGER /
INTERNATIONAL MANAGING DIRECTOR – ALTEN
In an era of rapid technological advancement, the life sciences sector is experiencing unprecedented transformations. Recent health crises have emphasised the need for agility in pharmaceutical development, where speed and efficiency are paramount.
At ALTEN, we don’t just keep pace with these changes—we shape them. Our innovative solutions drive progress in healthcare, biotechnology, and clinical research worldwide.
— In response to the dynamic demands of the life sciences domain, ALTEN has strategically evolved to provide adaptive and robust solutions. In 2022, we launched a dedicated Life Sciences division, combining our strengths with Aixial, managing CRO activities, and working together with Caduceum for Engineering and Manufacturing. We are now present throughout the entire value chain, from clinical research to post-market surveillance.
— Thanks to this consolidation, we now support over 300 clients, ranging from innovative startups to industry giants. Our goal is clear: providing tangible results for the clients we support, ultimately making a difference in patients’ lives.
Since acquiring SDG Group in 2020, specialising in business analytics, data management, AI, and performance management, ALTEN has developed operational and commercial synergies, strengthening our market position and offerings.
— At ALTEN, we prioritise client-focused innovation. Our commitment is demonstrated through initiatives like the Smart Factory 4.0 developed by ALTEN Labs, and through our internal hub of excellence, which fosters a true culture of innovation. With our global technical direction and flexible nearshore and offshore solutions, we provide bespoke, best-inclass support for our client’s projects. Many trains have to be adapted or renewed to meet evolving demands in terms of comfort and functionality, as well as technical requirements. For example, some metro lines delivered with a driver’s cab may eventually be converted to fully automatic operation. In terms of engineering, this means thinking ahead.
ALTEN’s expertise in automation, AI, and machine learning, accelerates drug discovery and development, ensuring fast and safe outcomes. Our groundbreaking work in biotechnology and cutting-edge healthcare technologies is central to our operations. Our teams of experts are dedicated to pushing the boundaries of what is possible, positioning us as a key player in the industry.
— As the life sciences sector remains crucial to global healthcare and economic stability, ALTEN will continue to advance, focusing on adaptability, collaboration, and excellence. Over the past 15 years, we have expanded our capabilities, with the aim of becoming a European market leader in the near future and extending our global reach.
Through dedication, innovation, and a shared vision, ALTEN is poised to make a significant impact in the life sciences industry.
We invite you to explore this magazine edition to discover just how we’re making this possible. Join us in charting a course towards a brighter and healthier future for all.
